Neurodegenerative Disorder Therapeutics Market By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, and Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2029

Neurodegenerative Disorder Therapeutics Market accounted for USD 9.32 Billion in 2019 and is estimated to be USD 21.3 Billion by 2029 and is anticipated to register a CAGR of 8.7%

Neurodegenerative disorders are a group of circumstances that affect the central nervous system. They involves both hereditary and sporadic conditions that are categorized by slow, irreversible, progressive dysfunction of the nervous system with the swelling degeneration of neurons. It causes symptoms such as memory loss, motor impairment, and declining cognitive ability. Currently, neurodegenerative disorders cannot be cured. Treatment is based on managing the disease indication in order to decrease the severity of symptoms and slow progression.

Impact of COVID-19 on the market

Several therapeutic regimens are being followed across the world in attempts to come up with a reliable treatment for Covid-19. The growing number of cases and fatalities is distressing mental health by elevating anxiety across the world. People who are already experiencing mental health problems are facing increased stress levels over the Covid-19 outbreak. This report will quantify the impact of this pandemic on the neurodegenerative disorder therapeutics market.

Increased prevalence of neurodegenerative disorder

Growth in the prevalence of neurodegenerative among the population drives the growth of neurodegenerative disorder therapeutics market. Rise in the number of geriatric population, results to the increased occurrence of neurodegenerative disorders. In 2017, as per World Population Prospects, the number of people above 60 years of age will increase from 962 million in 2017 to 2.1 billion in 2050 and it is estimated that people aged over 80 years will triple from 137 million in 2017 to 425 million in 2050. Further, according to data published by Alzheimer’s Association, around 5.8 million Americans are suffering with Alzheimer disease and this number is expected to grow to around 14 million by 2050. Thus, growing number of neurodegenerative diseases among the ageing population increases the demand for neurodegenerative disorder therapeutics thereby boosting the market growth.

Increasing collaborative partnerships

Prominent players involved in the neurodegenerative disorder therapeutics are adopting multiple strategic partnerships with government and non- government firms to discover and develop therapeutics for a range of neurodegenerative diseases. Additionally, manufacturers are also increasing their collaboration with other players in the market in order to expand their capabilities for research and development activities and to develop more effective therapeutic solutions to treat neurodegenerative disorders. For instance, in October 2019, Prevail Therapeutics Inc., a USA based Biotechnology Company collaborated with Lonza, a worldwide supplier of pharma & Biotech and specialty ingredients based in Switzerland. The collaboration aimed to develop and manufacture gene therapy programs for patients of neurodegenerative diseases.

Conversely, high rates of failure in research and development (R&D) and clinical trials have always been a major challenge in the neurodegenerative disorder therapeutics market.

The neurodegenerative disorder therapeutics market is segmented based on the indication type, drug type, distribution, and region.

On the basis of the indication type, the neurodegenerative disorder therapeutics market is segmented into Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington disease, and other indication types. Based on the drug type, the target market is segmented into N- methyl- D- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and other drug types. On the basis of distribution, the market is bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy.

Regional Insights:

In the region, the neurodegenerative disorder therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2018, the North America market dominated the target market and is expected to maintain its dominance over the forecast period. In U.S., neurodegenerative diseases have become more prevalent due to rising aging population. According to the data published by Parkinson’s Association in 2018, about 1.2 million people in the U.S are expected to be suffering from Parkinson’s disease by 2030. Along with the continuous growth in population, this disease is predicted to double between 2018 and 2026. Moreover, rising research and development (R&D) investments and favorable healthcare reimbursement policies is also propelling the target market in this region. The market in Asia Pacific is expected to witness a considerable CAGR mainly on account of increasing geriatric population.

Neurodegenerative Disorder Therapeutics Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029.  For the purpose of this study, has segmented the neurodegenerative disorder therapeutics market report based on indication type, drug type, distribution, and region.

Neurodegenerative Disorder Therapeutics Market, By Indication Type:

• Parkinson's Disease
• Alzheimer's Disease
• Multiple Sclerosis
• Huntington Disease
• Other Indication Types

Neurodegenerative Disorder Therapeutics Market, By Drug Type:

• N- methyl- D- aspartate Receptor
• Selective Serotonin Reuptake Inhibitor
• Dopamine Inhibitors
• Other Drug Types

Neurodegenerative Disorder Therapeutics Market, By Distribution:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

 Neurodegenerative Disorder Therapeutics Market, By Region:

• North America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • U.S.
  • Canada

The key players operating in the neurodegenerative disorder therapeutics market include Biogen, Pfizer, Sanofi, Novartis, Teva Pharmaceutical, Hoffmann- La Roche Ltd, UCB, ACADIA Pharmaceuticals Inc., Lundeck A/S and Boehringer Ingeiheim International GmbH. Manufacturers are investing heavily on R&D to offer a strong pipeline of drugs aimed at delivering improved patient care at low costs. Popular companies adopt strategies such as enhancement of product portfolio, regional expansion, and development of advanced diagnostic methods to improve the success rate of treatment. For instance, in February 2018, Abbevie, a USA based biopharmaceutical company collaborated with Voyager Therapeutics, a clinical stage gene therapy company based in USA. The collaboration was aimed to develop and commercialize treatments for Alzheimer’s disease and other tau-related (a protein) neurodegenerative diseases.

• Biogen
• Pfizer
• Sanofi
• Novartis
• Teva Pharmaceutical
• Hoffmann- La Roche, Ltd.
• UCB, ACADIA Pharmaceuticals, Inc.
• Lundeck A/S
• Boehringer Ingeiheim International GmbH